Fenster schließen  |  Fenster drucken

[posting]36482417[/posting]Du hast Recht, hier nochmals eine Meldung von Reuters!

UPDATE 1-BioMS multiple sclerosis drug fails mid-stage study
Fri Jan 30, 2009 8:53am EST Email | Print | Share| Reprints | Single Page[-] Text [+]
Market News
Stocks fall as economic worries bite, yen up | Video
Futures turn higher after GDP data | Video
Exxon Q4 profit down 33 percent, tops Wall Street
More Business & Investing News... Featured Broker sponsored link
Jan 30 (Reuters) - Canada's BioMS Medical Corp (MS.TO) said its lead drug for the treatment of multiple sclerosis failed to meet the main goal of a mid-stage study.

The drug dirucotide, which was being tested in patients with relapsing-remitting multiple sclerosis, was, however, well tolerated and met certain secondary endpoints related to the progression of the disease.:D

Multiple sclerosis, a condition where the immune system of the body attacks the protective cover of the nerves, is one of the leading causes of neurological disability in young adults.

BioMS, which signed a licensing and development deal with Eli Lilly (LLY.N) in 2007 for dirucotide, said it will continue to analyze the results of the mid-stage trial.

Dirucotide is also being studied in two late-stage trials -- in the United States and across Europe and Canada -- as a treatment for secondary progressive multiple sclerosis (SPMS).

The drug had received fast-track status from U.S. health regulators for the SPMS indication last September, a designation that is reserved for products intended to treat serious or life-threatening conditions with the potential to address unmet medical needs.

Shares of the Canadian biotechnology company closed at C$3.43 Thursday on the Toronto Stock Exchange. (Reporting by Vidya L Nathan in Bangalore; Editing by Himani Sarkar)

Hinter meinem smily steht versteckt daß die Endpunkte für Secondary Progressive....... MS, getroffen wurden, heißt das daß wir für die Phase III hoffnungsfroh sein können?

Also vereinfacht gefragt, unser Phase III Produkt wird zugelassen wenn es um die Verzögerung der Krankheit geht? (Und das klappt auch auch mit 5 Jahren), oder?

Danke für Deine Meinung!
 
aus der Diskussion: Bioms im Entscheidungsjahr auf dem Weg in die "Zweistelligkeit"?
Autor (Datum des Eintrages): Magnetfeldfredy  (30.01.09 15:20:26)
Beitrag: 27 von 179 (ID:36482550)
Alle Angaben ohne Gewähr © wallstreetONLINE